Axovant Sciences

 Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Friday, November 17, 2023

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points: 
  • Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
  • Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
  • I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

Retrieved on: 
Wednesday, June 21, 2023

BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.

Key Points: 
  • BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.
  • “We are very excited that Ilise will be stepping into the CEO role at Noema Pharma.
  • Ilise has the expertise and experience to lead Noema as the Company enters its next phase of growth,” said Jeffrey Jonas, M.D., Chairman of Noema Pharma’s Board of Directors.
  • “I am thrilled to assume this leadership position with Noema Pharma at such a critical phase in the Company’s growth,” said Dr. Lombardo.

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

Retrieved on: 
Wednesday, April 26, 2023

The poster, entitled, Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy, was presented by Daniel Claassen, MD, Professor of Neurology at Vanderbilt University Medical Center, and Principal Investigator in the bioMUSE study.

Key Points: 
  • The poster, entitled, Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy, was presented by Daniel Claassen, MD, Professor of Neurology at Vanderbilt University Medical Center, and Principal Investigator in the bioMUSE study.
  • The analysis was conducted to determine the utility of quantitative wearable sensors in 17 participants with early stage (less than three years of motor symptoms) multiple system atrophy (MSA).
  • “This analysis from bioMUSE demonstrates that wearable sensors can quantify motor impairment in MSA patients that is not captured by neurological examination,” said David Stamler, M.D., Chief Executive Officer, Alterity.
  • Specifically, sensor parameters correlated strongly with clinical scales of motor impairment and may be useful in assessing disease progression.

AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

Retrieved on: 
Tuesday, February 1, 2022

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean OBryan as chief regulatory officer.

Key Points: 
  • AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean OBryan as chief regulatory officer.
  • We are delighted to bring Sean OBryan on board as we advance multiple programs in lysosomal disorders.
  • OBryan has more 30 years of experience leading regulatory efforts in the biotech industry.
  • He joins AVROBIO from Freeline Therapeutics, where he served as the senior vice president and head of Global Regulatory Affairs.

Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

Retrieved on: 
Tuesday, November 9, 2021

"I am very pleased to welcome Catherine and Ilise to the board of Noema Pharma.

Key Points: 
  • "I am very pleased to welcome Catherine and Ilise to the board of Noema Pharma.
  • The two new appointments further expand the Company's board and follow the recent appointment of Jeffrey Jonas MD as the Chairman of the Board of Directors.
  • "I am delighted to be joining Noema Pharma's board and I'm looking forward to working with Noemas dedicated and talented executive team," said Ilise Lombardo MD, Board Member of Noema Pharma.
  • Catherine Moukheibir currently serves on the Board of Directors at DNA Script, Asceneuron, Biotalys, CMR Surgical, Ironwood Pharmaceuticals and Orphazyme.

ReCode Therapeutics Appoints Nicholas P. France, M.D., as Senior Vice President of Clinical Development

Retrieved on: 
Monday, September 27, 2021

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Nicholas P. France, M.D., MRCPCH, as senior vice president, clinical development.

Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Nicholas P. France, M.D., MRCPCH, as senior vice president, clinical development.
  • Nick has had an impressive career successfully leading clinical and regulatory activities for novel therapeutics at all stages of development, said David Lockhart, Ph.D., CEO and President, ReCode Therapeutics.
  • Dr. France is an accomplished rare disease clinical drug developer with extensive clinical, regulatory and business development expertise across all phases of development.
  • He was senior director, clinical development for neurosciences and rare diseases with Roivant Sciences and Axovant Sciences, and executive director, clinical development at Strongbridge Biopharma.

Sio Gene Therapies to Present at the UBS Global Healthcare Virtual Conference

Retrieved on: 
Wednesday, May 19, 2021

b'Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.

Key Points: 
  • b'Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson\xe2\x80\x99s disease, which affects millions of patients globally.
  • Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.

Sio Gene Therapies to Participate in Upcoming Conferences

Retrieved on: 
Monday, March 29, 2021

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences in April.

Key Points: 
  • NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences in April.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies.
  • Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.

Centessa Pharmaceuticals Appoints Gregory Weinhoff, M.D., MBA, as Chief Financial Officer and Expands Board of Directors

Retrieved on: 
Thursday, March 11, 2021

Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D., joined Centessas board of directors effective February 23, 2021.

Key Points: 
  • Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D., joined Centessas board of directors effective February 23, 2021.
  • The enhanced scale and resources of Centessa, combined with the benefits of asset-centricity, can further accelerate development of important therapies, said Dr. Weinhoff.
  • Dr. Weinhoff joins Centessa after most recently co-founding and serving as chief financial and business officer of Arvelle Therapeutics B.V., which was acquired by Angelini Pharma in 2021 for $960 million.
  • Previously, Dr. Weinhoff served as chief financial officer at Axovant Sciences, Inc., where he led financial functions and the execution of several private and public financings.

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)

Retrieved on: 
Wednesday, February 3, 2021

We look forward to evaluating the results of this study and advancing the first potentially disease-modifying treatment option for patients with GM2.

Key Points: 
  • We look forward to evaluating the results of this study and advancing the first potentially disease-modifying treatment option for patients with GM2.
  • AXO-AAV-GM2 has been granted Orphan Drug and Rare Pediatric Disease Designation by the FDA and is the first investigational gene therapy to enter clinical trials for GM2 gangliosidosis.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally.